Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
| Products/Services Used |
Details |
Operation |
| Catalog Antibody |
Gastric cancer (GC) is a common cancer in Asia and currently lacks a targeted therapy approach.
Mesothelin (MSLN) has been reported to be expressed in GC tissue and could be targeted by
chimeric antigen receptor (CAR) T cells. Mesothelin targeting CAR-T has been reported …containing the DAP10 cytoplasmic sequence were synthesized by Genscript (Nanjing) Co |
Get A Quote |
Gastric cancer (GC) is a common cancer in Asia and currently lacks a targeted therapy approach. Mesothelin (MSLN) has been reported to be expressed in GC tissue and could be targeted by chimeric antigen receptor (CAR) T cells. Mesothelin targeting CAR-T has been reported in mesothelioma， lung cancer， breast cancer， and pancreas cancer. However， the feasibility of using anti-MSLN CAR T cells to treat GC remains to be studied.
Gastric cancer (GC) is a common cancer in Asia and currently lacks a targeted therapy approach. Mesothelin (MSLN) has been reported to be expressed in GC tissue and could be targeted by chimeric antigen receptor (CAR) T cells. Mesothelin targeting CAR-T has been reported in mesothelioma， lung cancer， breast cancer， and pancreas cancer. However， the feasibility of using anti-MSLN CAR T cells to treat GC remains to be studied.
Chimeric antigen receptor T cells，Gastric cancer，Immunodeficient mice，Immunotherapy，Mesoth
